|
|
 |
 |
| |
 Printable version |
Acute coronary syndrome |
MT Cardio. Volume 3, Number 5, 338-43, Septembre-Octobre 2007, Dossier – Nouveaux antithrombotiques
|
 Résumé
Article gratuit
|
Author(s) : Gérard Helft |
Summary : Acute coronary syndromes are the main cause of hospitalizations in coronary care units. ACS diagnosis is initially given in doubtful cases in order not to misdiagnose some of them. However, it may be necessary to correct this diagnosis later. The pathophysiological substrate of rupture/ersosion is well known but the factors leading to this are less well understood. For this reason, atherothrombotic disease remains a life-threatening state. Diagnosis and short-term risk stratification of non-ST-segment elevation acute coronary syndromes (NSTE-ACS) should be based on a combination of clinical history, symptoms, ECG, biomarkers, and risk score results. This will determine the need for an urgent invasive strategy, i.e. coronary angiography (in the first 72 hours). In risk stratification, the cardiac troponins are important. They are sensitive, useful, and easy markers. Their increase reveals myocardial damage. Anti-thrombotic agents, anticoagulants and antiplatelets agents have a central role in improving the ACS prognosis. Attention has recently been drawn to the bleeding risk that is the most frequent non-ischaemic complication. Bleeding has an impact on the prognosis. Anti-ischaemic treatments and statins are also part of ACS treatment. |
Keywords : acute coronary syndrome, thrombosis, guidelines, risk stratification |
|
